Publication at Faculty of Medicine in Hradec Králové |
2021
Abstract
There has been tremendous progress in the treatment of MS over recent years. The concept of early treatment to achieve better outcomes in MS has clearly emerged, fully supported by long-term data.
The effi cacy of anti-CD20 monoclonal antibodies in the treatment of MS has been confirmed in clinical trials. Ofatumumab is a fully-humanized anti-CD20 monoclonal antibody approved for the treatment of adult patients with relapsing-remitting MS.
Ofatumumab showed high efficacy and a favorable safety profi le in phase III clinical trials, off ering the fi rst B-cell therapy that can be subcutaneously self-administered at home.